The International AIDS Society (IAS) announced a new collaboration with Janssen, the pharmaceutical companies of Johnson & Johnson, to support the IAS Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) program. Janssen is providing a grant to CIPHER to accelerate research and advocacy for children and adolescents living with HIV. Additionally, IAS and Janssen are partnering on the New Horizons initiative focused on children who have developed resistance to first-line HIV treatments. The partnerships aim to ensure all children have access to HIV care and treatment.

1. PRESS RELEASE
IAS Welcomes Janssen to CIPHER program
Collaboration to support advances in pediatric HIV treatment and care in low-resource settings
GENEVA, Switzerland, December 11 2014 — As part of its continued commitment to ending pediatric
HIV globally, the International AIDS Society (IAS) today announced a new collaboration with Janssen, the
pharmaceutical companies of Johnson & Johnson in the IAS Collaborative Initiative for Paediatric HIV
Education and Research (CIPHER) program. In support of CIPHER, Janssen is providing a grant to
accelerate research and advocacy around good clinical practices for and delivery of services to
vulnerable children, and adolescents living with HIV.
According to the latest data from UNAIDS, while an estimated 12.9 million people were on HIV treatment
by the end of 2013, only one quarter of the 3.2 million children in need were able to access treatment. As
a result of this imbalance, more than 500 children die of AIDS every day. This new grant from Janssen
will help combat these trends and ensure that the needs of children living with HIV are brought to the
forefront of international discussions.
“We are very excited about this new collaboration with Janssen,” said Marissa Vicari, CIPHER Project
Manager. “The private sector is an integral player in the fight against pediatric HIV, and Johnson &
Johnson has a long legacy in promoting the health of children. We know that our combined efforts will
have a tremendous impact on children in need.”
The Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) is a flagship paediatric
research initiative of the International AIDS Society (IAS), aimed at optimizing clinical management and
delivery of services to infants, children and adolescents affected by HIV in resource-limited settings
through advocacy and research promotion. Initiated in 2012, the founding sponsor of CIPHER is ViiV
Healthcare.
To help tackle the specific challenge of HIV treatment failure in children and adolescents, IAS has further
extended its partnership with Janssen by joining the New Horizons Advancing Pediatric HIV Treatment
initiative. This collaborative program is focused on advancing knowledge and action around the unique
needs of children who have grown resistant to first-line HIV medicines, in partnership with Janssen, the
Elizabeth Glaser Pediatric AIDS Foundation, Supply Chain Management System, and MAP International.
“Working with CIPHER is an important step in our mission to ensure that all children and adolescents
living with advanced HIV have access to the care they need to stay healthy,” said Perry Mohammed,
M.D., Global Medical Affairs Lead at Janssen. “One of the founding principles of the New Horizons
initiative is an emphasis on partnerships and cross-sector collaboration. Janssen and CIPHER’s common

2. vision of a world where no child dies of HIV will only be realized when all stakeholders join together and
commit to fighting this battle as one, unified front.”
While the international community has dramatically scaled-up access to HIV treatment around the world,
advances in pediatric care lag behind. Additionally, the adolescent HIV mortality rate – which is declining
amongst all other age groups – is growing. More now than ever, programs like CIPHER and New
Horizons are needed to ensure that these trends are reversed and to safeguard the health of children all
over the world.
###
About CIPHER:
The Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) is a flagship paediatric
research initiative of the International AIDS Society (IAS), aimed at optimizing clinical management and
delivery of services to infants, children and adolescents affected by HIV in resource-limited settings
through advocacy and research promotion. Initiated in 2012, CIPHER is supported by an unrestricted
grant from ViiV Healthcare’s Paediatric Innovation Seed Fund. The content and structure of the project is
guided by paediatric experts convened by the IAS.
The main objectives of CIPHER are:
 Promoting and investing in targeted research to address knowledge gaps/priority questions to
optimize service delivery and clinical management of infants and children in resource-limited
settings.
 Convening stakeholders and establishing collaboration mechanisms to strengthen
communication, knowledge transfer and exchange among paediatric HIV cohorts.
 Advocacy and outreach to support evidence-informed clinical, policy and programmatic decision
making.
CIPHER is designed to complement existing global initiatives and create partnerships with other
organizations to maximize investment in paediatric HIV research and improve paediatric health outcomes.
The first phase of the project consisted of building a solid scientific and programmatic foundation. A
comprehensive needs assessment was conducted, including a literature review and key informant
interviews with experts, which outlined a set of research priorities that has been used to inform and guide
CIPHER.
About the IAS
The International AIDS Society (IAS) is the world's leading independent association of HIV professionals,
with over 13,000 members from more than 180 countries working at all levels of the global response to
AIDS. The IAS members include researchers from all disciplines, clinicians, public health and community
practitioners on the frontlines of the epidemic, as well as policy and programme planners. The IAS is
custodian of the biennial International AIDS Conference, which will be held in Durban, South Africa, 17-22
July 2016 and lead organizer of the IAS Conference on HIV Pathogenesis, Treatment and Prevention,
which will be held in Vancouver, British Columbia, Canada, 19-22 July 2015.
www.iasociety.org | www.ias2015.org | www.aids2016.org

3. About Johnson & Johnson
Caring for the world, one person at a time…inspires and unites the people of Johnson & Johnson. We
embrace research and science ‒ bringing innovative ideas, products and services to advance the health
and well-being of people. Our approximately 128,000 employees at more than 275 Johnson &
Johnson operating companies work with partners in health care to touch the lives of over a billion people
every day, throughout the world.
About the Janssen Pharmaceutical Companies of Johnson & Johnson
The Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving
the most important unmet medical needs of our time, including oncology (e.g., multiple myeloma and
prostate cancer), immunology (e.g., rheumatoid arthritis, inflammatory bowel disease and psoriasis),
neuroscience (e.g., schizophrenia, dementia and pain), infectious disease (e.g., HIV/AIDS, Hepatitis C
and tuberculosis), and cardiovascular and metabolic diseases (e.g., diabetes). Driven by our commitment
to patients, we develop sustainable, integrated healthcare solutions by working side-by-side with
healthcare stakeholders, based on partnerships of trust and transparency. To learn more,
visit www.janssen.com.
For more information:
Contact:
Lynda Piper-Roche
Communications Officer
International AIDS Society
Geneva | Switzerland
+41 22 7100 822